Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2

Merck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma Letter

GE HealthCareGE HealthCare’s stock plunges 13% as supply chain costs bite - Medical Device Network

BioPharma DiveMerck still sees ‘compelling’ outlook for Terns leukemia drug

Merck & Co.Merck & Co lifts outlook as Keytruda growth offsets acquisition hit - The Pharma Letter

CellProteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function

CellDifferential inhibition of Morbillivirus and Henipavirus polymerases by ERDRP-0519 and structure-guided inhibitor optimization

BioPharma DiveUniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy

Merck & Co.Merck's growth products Winrevair, Ohtuvayre trending in opposite directions - Fierce Pharma

Endpoints NewsAvalyn's upsized IPO; Alector ends another study in GSK partnership

Endpoints NewsAnalysts focus on three programs in big year for Bristol Myers

BioPharma DiveLilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

Endpoints NewsXTL Bio to acquire psychedelic biotech; WuXi AppTec’s Q1 revenue rise